Even in the face of these less than stellar results, Dr. Goadsby said he remained hopeful that these compounds have potential for the prevention of migraine, and he is involved in a trial of the compound for this effect, adding that using lower doses over longer periods of time for prevention might avoid the side effects observed in this trial.
Summary and comments:
At this time, there are no medications on the market that were developed specifically for Migraine prevention. All of the 100 plus medications in use are "hand-me-down" medications, medications that were originally developed for other purposes. The possible development of a new class of medications is exciting and hope inspiring.
Even though ADX10059 showed problems in this phase IIa trial, it's still early. Hopefully, it will prove to be a safe and effective preventive even if it doesn't work out as a Migraine abortive medication.
____________
Resources:
1 Fiore, Kristina. "AAN: Glutamate Receptor Inhibitors May Help Migraine." MedPage Today. April 30, 2009.
2 Press Release. "Data Suggests Glutamate Receptor "mGluR5" is Clinically Relevant for Migraine." Adex Pharmaceuticals. Geneva, Switzerland. April 29, 2009.
3 Goadsby PJ, et al "Investigation of the role of mGluR5 inhibition in migraine: A proof-of-concept study of ADX10059 in acute treatment of migraine." AAN 2009; Abstract P06.006.
© Teri Robert, 2009. Last updated May 11, 2009.
